MIRA
INFORM REPORT
|
Report Date : |
16.12.2013 |
IDENTIFICATION DETAILS
|
Name : |
TEVAPHARM INDIA PRIVATE LIMITED [w.e.f. 07.09.2011] |
|
|
|
|
Formerly Known
As : |
RATIOPHARM INDIA PRIVATE LIMITED |
|
|
|
|
Registered
Office : |
402, Omega, Hiranandani Garden, Powai, Mumbai-400076, Maharashtra |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as
on) : |
31.12.2012 |
|
|
|
|
Date of
Incorporation : |
01.12.2000 |
|
|
|
|
Com. Reg. No.: |
11-129835 |
|
|
|
|
Capital Investment
/ Paid-up Capital : |
Rs.1114.438
Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U33111MH2000FTC129835 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
MUMR10449F |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAECR7561F |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business
: |
Subject is engaged in manufacturing of formulation and also providing
contract testing, research services, business development, procurement and pharma
co vigilance related support services. |
|
|
|
|
No. of Employees
: |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (52) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 11190000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well established company having a good track record.
Financially company seems to be performing well. Performance capability is
high. Trade relations are reported to be fair. Business is active. Payments
are reported to be regular and as per commitments. The company can be considered for normal business dealings at usual
trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very
High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
INDIAN ECONOMIC OVERVIEW
The current downturn
provides an opportunity to push ahead with reforms to accelerate growth, says
the latest India Development Update report released by the World Bank. The
report says that the adverse effects of rupee depreciation are likely to be
offset by the gains in the exports performance due to improved external
competitiveness. Since May this year, the local currency has depreciated
substantially and fell to a record level of Rs 68.85 to a dollar on August, 28.
A stagflation like
situation appears to have arisen as inflation jumped to an eight month high of
6.46 % for the month of September. It is up from 6.10 % in August. Growth
continues to be muted with factory output plunging to 0.6 % in August.
Onion prices have risen nearly 300 % from last September. Vegetables cost
nearly 90 % more than they did last year. Wake up to the economic contribution
of slum dwellers. They contribute more than 7.5 % to the country’s gross
domestic product, according to a recent study conducted in 50 top cities.
136000 estimated number
of jobs created during the second quarter of the current financial year. 50000
estimated number of additional jobs in the field of corporate social
responsibility in the coming years.
The International
Finance Corporation expects to come out with its rupee linked bonds issue
before the end of 2013 as a part of its plan to raise $ 1 billion. The Apple
iPhone 5c (Rs 41900 for 16 GB variant) and 5s (Rs 53500 for 16GB variant) has
been launched in India from 1st November.
The Land Acquisition
Act to provide just and fair compensation to farmers will come into force from
January 1 next year, said Rural Development Minister Jairam Ramesh. The Act
replaces a 119 year old registration. The Securities and Exchange Board of
India has approved the trading of currency futures on the Bombay Stock
Exchange. The exchange plans to launch the currency futures platform with
advanced trading technology by the end of November.
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2012.
LOCATIONS
|
Registered Office : |
402, Omega, Hiranandani Garden, Powai, Mumbai-400076, Maharashtra,
India |
|
Tel. No.: |
91-22-66412100 / 101 |
|
Fax No.: |
91-22-25705991 |
|
E-Mail : |
|
|
|
|
|
Factory : |
Plot A-1, Phase 1-A Averna, Verna, Goa, India |
DIRECTORS
AS ON 29.06.2013
|
Name : |
Eyal Arieli |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
PO Box 101, Kfar Harif - 79830, Israel |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Birth/Age : |
13.08.1961 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Appointment : |
04.10.2011 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Din No.: |
03360084 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other Directorship :
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Eran Katz |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
Apartment 45206, Rakefet 10, Hod Hasharon, Israel |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Birth/Age : |
30.09.1964 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Appointment : |
27.06.2012 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Din No.: |
03588218 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other Directorship :
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Kapildev Sapra |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
M-34, Saket, New Delhi-110017, India |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Birth/Age : |
05.08.1972 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Appointment : |
27.06.2012 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Din No.: |
00130600 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other Directorship :
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Puru Aggarwal |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
19/702, Eastend Apartment, Mayur Vihar, Phase 1 Extension,
Delhi-110096, India |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Birth/Age : |
03.01.1967 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Appointment : |
28.06.2013 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Din No.: |
02519685 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other Directorship :
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Ramachandra Ganapati Naik |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
Row House, 9, Eternity, Kanakia Spaces, Teen Hath Naik, Thane-400602,
Maharashtra, India |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Birth/Age : |
12.05.1954 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Appointment : |
28.06.2013 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Din No.: |
00297009 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other Directorship :
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
KEY EXECUTIVES
|
Name : |
Mr. Ramesh Ramchand Sadani |
|
Designation : |
Secretary |
|
Address : |
71-A, Collectors Colony, Mahul Road, Chembur, Mumbai-400071,
Maharashtra, India |
|
Date of Birth/Age : |
24.07.1966 |
|
Date of Appointment : |
29.03.2005 |
|
Pan No.: |
AAKPS6202Q |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
AS ON 29.06.2013
|
Names of Shareholders |
|
No. of Shares |
|
Ratiopharm GmbH, Germany |
|
50000000 |
|
Teva Pharmaceutical Investment Singapore Pte Limited, Singapore |
|
61443750 |
|
|
|
|
|
TOTAL
|
|
111443750 |
AS ON 29.06.2013
|
Equity Share Breakup |
|
Percentage of Holding |
|
Category |
|
|
|
Foreign holdings [Foreign institutional investors, Foreign Companies, Foreign Financial Institutions, Non-resident Indian or Overseas corporate bodies or others] |
|
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Subject is engaged in manufacturing of formulation and also providing
contract testing, research services, business development, procurement and
pharma co vigilance related support services. |
GENERAL INFORMATION
|
No. of Employees : |
Not Available |
|
|
|
|
Bankers : |
·
State Bank of India ·
Deutsche Bank ·
Bank of Baroda |
|
|
|
|
Facilities : |
-- |
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
BSR and Company Chartered Accountants |
|
Address : |
1st Floor, Lodha Excelus, Apollo Mills Compound, N.M Joshi
Marg, Mahalaxmi, Mumbai-400011, Maharashtra, India |
|
PAN No: |
AAIFB0630K |
|
|
|
|
Holding Company : |
Teva
Pharmaceutical Investments Singapore PTE Limited |
|
|
|
|
Associates : |
·
Teva Pharmaceutical and Chemical Industries India
Private Limited [U24230DL2003FTC183289] ·
Ratiopharm GmbH, Germany ·
Teva UK Ltd, United Kingdom ·
Teva Operations Poland Spzoo, Poland ·
Teva Pharmacutical Europe B.V, Netherlands ·
Teva Pharmaceutical USA ·
Teva Canada Limited ·
Teva Pharma Produtos Farmaceuticos Lda ·
Teva Pharmaceutical Works PLC ·
Teva India Private Limited ·
Ratiopharm International GmbH |
CAPITAL STRUCTURE
AS ON 31.03.2012
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
200000000 |
Equity Shares |
Rs.10/- each |
Rs.2000.000 Millions |
|
150000000 |
Preferences Shares |
Rs.10/- each |
Rs.1500.000 Millions |
|
|
|
|
|
|
|
TOTAL
|
|
Rs.3500.000
Millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
111443750 |
Equity Shares |
Rs.10/- each
|
Rs.1114.438
Millions |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE SHEET
|
SOURCES
OF FUNDS |
|
31.12.2012 |
31.12.2011 |
|
I.
EQUITY AND LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
|
1114.438 |
500.000 |
|
(b) Reserves & Surplus |
|
1683.809 |
369.498 |
|
(c) Money received against
share warrants |
|
0.000 |
0.000 |
|
|
|
|
|
|
(2)
Share Application money pending allotment |
|
0.000 |
0.000 |
|
Total Shareholders’ Funds (1) + (2) |
|
2798.247 |
869.498 |
|
|
|
|
|
|
(3) Non-Current Liabilities |
|
|
|
|
(a) long-term
borrowings |
|
0.000 |
494.099 |
|
(b) Deferred tax liabilities (Net) |
|
0.000 |
0.000 |
|
(c) Other long
term liabilities |
|
0.000 |
0.000 |
|
(d) long-term
provisions |
|
12.602 |
5.846 |
|
Total Non-current
Liabilities (3) |
|
12.602 |
499.945 |
|
|
|
|
|
|
(4) Current Liabilities |
|
|
|
|
(a)
Short term borrowings |
|
0.000 |
0.000 |
|
(b)
Trade payables |
|
273.608 |
402.110 |
|
(c)
Other current liabilities |
|
521.700 |
246.455 |
|
(d) Short-term
provisions |
|
123.775 |
0.534 |
|
Total Current
Liabilities (4) |
|
919.083 |
649.099 |
|
|
|
|
|
|
TOTAL |
|
3729.932 |
2018.542 |
|
|
|
|
|
|
II.
ASSETS |
|
|
|
|
(1) Non-current assets |
|
|
|
|
(a)
Fixed Assets |
|
|
|
|
(i)
Tangible assets |
|
1380.382 |
765.448 |
|
(ii)
Intangible Assets |
|
1.295 |
0.000 |
|
(iii)
Capital work-in-progress |
|
85.738 |
38.228 |
|
(iv) Intangible assets under development |
|
0.000 |
0.000 |
|
(b) Non-current
Investments |
|
0.000 |
0.000 |
|
(c) Deferred tax
assets (net) |
|
99.900 |
64.191 |
|
(d) Long-term Loan and Advances |
|
50.597 |
43.050 |
|
(e) Other
Non-current assets |
|
0.000 |
0.000 |
|
Total Non-Current
Assets |
|
1617.912 |
910.917 |
|
|
|
|
|
|
(2) Current assets |
|
|
|
|
(a)
Current investments |
|
0.000 |
0.000 |
|
(b)
Inventories |
|
328.735 |
715.112 |
|
(c)
Trade receivables |
|
362.588 |
258.311 |
|
(d) Cash
and cash equivalents |
|
1342.528 |
55.594 |
|
(e)
Short-term loans and advances |
|
75.604 |
77.019 |
|
(f)
Other current assets |
|
2.565 |
1.589 |
|
Total
Current Assets |
|
2112.020 |
1107.625 |
|
|
|
|
|
|
TOTAL |
|
3729.932 |
2018.542 |
|
SOURCES OF FUNDS |
|
|
31.12.2010 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
|
|
500.000 |
|
|
2] Share Application Money |
|
|
0.000 |
|
|
3] Reserves & Surplus |
|
|
255.959 |
|
|
4] (Accumulated Losses) |
|
|
0.000 |
|
|
NETWORTH |
|
|
755.959 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
|
|
0.000 |
|
|
2] Unsecured Loans |
|
|
428.137 |
|
|
TOTAL BORROWING |
|
|
428.137 |
|
|
DEFERRED TAX LIABILITIES |
|
|
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
|
|
1184.096 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
|
|
807.994 |
|
|
Capital work-in-progress |
|
|
39.045 |
|
|
|
|
|
|
|
|
INVESTMENT |
|
|
0.000 |
|
|
DEFERREX TAX ASSETS |
|
|
38.399 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
|
|
209.778 |
|
|
Sundry Debtors |
|
|
191.342 |
|
|
Cash & Bank Balances |
|
|
36.348 |
|
|
Other Current Assets |
|
|
2.793 |
|
|
Loans & Advances |
|
|
73.989 |
|
Total
Current Assets |
|
|
514.250 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
|
|
94.037 |
|
|
Other Current Liabilities |
|
|
108.555 |
|
|
Provisions |
|
|
13.000 |
|
Total
Current Liabilities |
|
|
215.592 |
|
|
Net Current Assets |
|
|
298.658 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
|
|
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
|
|
1184.096 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.12.2012 |
31.12.2011 |
31.12.2010 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
|
|
|
|
|
|
Other Income |
|
|
|
|
|
|
TOTAL (A) |
3399.376 |
1472.452 |
817.542 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Office Expenses |
|
|
|
|
|
|
Administrative Expenses |
|
|
|
|
|
|
Advertising Expenses |
|
|
|
|
|
|
TOTAL (B) |
2552.312 |
1161.346 |
479.577 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
847.064 |
311.106 |
337.965 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
8.696 |
11.140 |
6.328 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
838.368 |
299.966 |
331.637 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
169.979 |
149.039 |
128.889 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
668.389 |
150.927 |
202.748 |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
214.291 |
37.388 |
87.246 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-H) (I) |
454.098 |
113.539 |
115.502 |
|
|
|
|
|
|
|
|
|
|
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
369.499 |
255.959 |
140.457 |
|
|
|
|
|
|
|
|
|
|
BALANCE CARRIED
TO THE B/S |
823.597 |
369.498 |
255.959 |
|
|
|
|
|
|
|
|
|
|
EARNINGS IN
FOREIGN CURRENCY |
3340.097 |
1446.255 |
794.646 |
|
|
|
|
|
|
|
|
|
|
IMPORTS |
|
|
|
|
|
|
|
Raw Materials |
NA |
406.268 |
47.234 |
|
|
|
Packing materials |
NA |
5.570 |
1.293 |
|
|
|
Capital Goods |
NA |
56.591 |
62.985 |
|
|
|
Stores and spares |
NA |
24.567 |
4.947 |
|
|
TOTAL IMPORTS |
NA |
492.996 |
116.459 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
4.07 |
-- |
-- |
|
KEY RATIOS
|
PARTICULARS |
|
31.12.2012 |
31.12.2011 |
31.12.2010 |
|
PAT / Total Income |
(%) |
13.36 |
7.71 |
14.13 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
18.86 |
7.88 |
15.33 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.24 |
0.17 |
0.27 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Debt/Networth) |
|
0.00 |
0.57 |
0.57 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
2.30 |
1.71 |
2.39 |
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check List by
Info Agents |
Available in
Report (Yes / No) |
|
1] |
Year of Establishment |
Yes |
|
2] |
Locality of the firm |
Yes |
|
3] |
Constitutions of the firm |
Yes |
|
4] |
Premises details |
No |
|
5] |
Type of Business |
Yes |
|
6] |
Line of Business |
Yes |
|
7] |
Promoter's background |
Yes |
|
8] |
No. of employees |
No |
|
9] |
Name of person contacted |
No |
|
10] |
Designation of contact person |
No |
|
11] |
Turnover of firm for last three years |
Yes |
|
12] |
Profitability for last three years |
Yes |
|
13] |
Reasons for variation <> 20% |
-- |
|
14] |
Estimation for coming financial year |
No |
|
15] |
Capital in the business |
Yes |
|
16] |
Details of sister concerns |
Yes |
|
17] |
Major suppliers |
No |
|
18] |
Major customers |
No |
|
19] |
Payments terms |
No |
|
20] |
Export / Import details (if applicable) |
No |
|
21] |
Market information |
-- |
|
22] |
Litigations that the firm / promoter involved in |
-- |
|
23] |
Banking Details |
Yes |
|
24] |
Banking facility details |
No |
|
25] |
Conduct of the banking account |
-- |
|
26] |
Buyer visit details |
-- |
|
27] |
Financials, if provided |
Yes |
|
28] |
Incorporation details, if applicable |
Yes |
|
29] |
Last accounts filed at ROC |
Yes |
|
30] |
Major Shareholders, if available |
Yes |
|
31] |
PAN of Proprietor/Partner/Director, if available |
No |
|
32] |
Date
of Birth of Proprietor/Partner/Director, if available |
Yes |
|
33] |
Voter ID No of Proprietor/Partner/Director, if available |
No |
|
34] |
External Agency Rating, if available |
No |
INDEX OF CHARGES: NO CHARGES EXIST FOR COMPANY
OPERATIONS:
The Company has
achieved a total income of Rs. 3399.376 Millions in the current year compared
to Rs. 1472.452 Millions in the previous year from export of pharma products
and R and D Pharma and Technical Services, thus registering 130 % increase in
sales growth over the previous year. For the year, the profit after tax was Rs.
454.098 Millions as against Rs. 113.539 Millions in the previous year. There
were two fire incidents at its factory site at Verna, Goa as a result of which
certain fixed assets were burnt/ damaged and the claims are in process by the
insurance company. The Company has acquired industrial land on lease from the
Gujarat Industrial Development Corporation (GIDC) at Sanand, Ahmedabad for its
OTC project. During the year, an amount Rs. 646.725 Millions has been incurred
on the said OTC project
|
Unsecured Loan |
As
on 31.03.2012 [Rs.
in Millions] |
As
on 31.03.2011 [Rs.
in Millions] |
|
Long Term
Borrowings |
|
|
|
Loans and advances from related parties |
0.000 |
494.099 |
|
|
|
|
|
TOTAL
|
0.000 |
494.099 |
AS PER WEBSITE DETAILS
Press Release
TEVA IN-FOCUS: A WEBINAR SERIES FOR THE INVESTMENT COMMUNITY FOCUSING ON
TEVA’S R&D ACTIVITIES
December 04, 2013
New Therapeutic Entities (NTE) - from Process
to Product
Teva unveils new pipeline assets from its 2013
NTE program
- Embargoed: December 4th, 8:00am Eastern Time
(2nd Teva R and D In-Focus Webinar) –
JERUSALEM--(BUSINESS WIRE)--Dec. 4, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that 15 new
projects have entered its development pipeline from its New Therapeutic
Entities (NTE) program.
Launched one year ago, the NTE program has
delivered new pipeline assets in major therapeutic areas, including:
Innovation in the abuse deterrent delivery of
opioids for pain
Significant development in the delivery of a
key schizophrenia treatment
New targeted release approach to improve the safety
profile of a common treatment for Crohn's Disease
Based on known molecules that are formulated,
delivered, or used in a novel way to address unmet patient need and improve
adherence and efficacy, the NTE program is a major element in Teva's strategy
for growth. It was established to leverage Teva's vast molecular catalogue,
advanced technological capabilities and extensive specialty drug development
expertise. The program was designed to "industrialize" the process of
generating, evaluating and rapidly and cost-effectively developing new
specialty medicine concepts, which bring distinct and definite advantages over
current therapies
"Bringing 15 new development programs
into the pipeline in one year is exciting," said Dr. Michael Hayden,
Teva's President of Global R and D and Chief Scientific Officer.
"Moreover, the products we will be developing represent genuine advances
on existing therapies, and will deliver real benefit to patients. The rigorous
process we have established to identify and evaluate these projects will
support successful delivery of these new treatments for the patients that need
them."
An infographic overview of the process and
projects can be accessed here. However, the full NTE story can be seen and
heard during the Teva In-Focus NTE webinar (see below for log-in details). The
webinar will include an in-depth review of certain key projects from the 2013
program, outlining the global market and unmet needs for each one. It will
highlight the approach and technologies Teva is using to improve upon known
molecules to address these unmet needs, and provide a clear picture of the
development plans and expected therapeutic benefits.
Dr. Michael Hayden, Teva’s President of Global
R and D and Chief Scientific Officer, will lead the webinar and will be joined
by key leaders from Teva’s NTE program.
TEVA AND TAKEDA ANNOUNCE AGREEMENT FOR GLATIRAMER ACETATE FOR MULTIPLE
SCLEROSIS TREATMENT IN JAPAN
December 04, 2013
JERUSALEM AND OSAKA, Japan--(BUSINESS
WIRE)--Dec. 4, 2013-- Teva Pharmaceutical Industries Limited (NYSE:TEVA) and
Takeda Pharmaceutical Company Limited (Takeda) today announced the signing
earlier this year of an agreement in which Teva licensed to Takeda the right to
commercialize Teva’s innovative glatiramer acetate ( active ingredient)
formulation for the treatment of multiple sclerosis, in Japan. Teva and Takeda
are currently working on further agreements in connection with the
implementation of this license.
Developed by Teva, glatiramer acetate for
injection is indicated for the reduction of the frequency of relapses in
relapsing-remitting multiple sclerosis, including patients who have experienced
a first clinical episode and have MRI features consistent with multiple
sclerosis. It is considered standard treatment for relapsing-remitting multiple
sclerosis, and is now approved in 55 countries worldwide. Teva’s glatiramer
acetate is designated as an orphan drug in Japan, and currently is under
development as an Unapproved New Drug by Teva Pharmaceutical K.K., a subsidiary
of Teva, at the request of the Japanese Ministry of Health, Labor and Welfare.
Under the terms of the agreement, Teva will
grant Takeda commercialization rights in Japan, and Takeda will submit a New
Drug Application for registration of glatiramer acetate in Japan. The financial
details of the agreement are confidential.
Teva and Takeda will work under close
cooperation so that both parties can provide a new treatment option to patients
with multiple sclerosis in Japan as early as possible, where the current
available therapies are still limited.
TEVA TO HOST 2014 BUSINESS OUTLOOK CONFERENCE CALL AND WEBCAST ON
DECEMBER 10, 2013
December 04, 2013
JERUSALEM--(BUSINESS WIRE)--Dec. 4, 2013--
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that it will
host a conference call and live webcast on Tuesday, December 10, 2013 at 8:00
a.m. EST to communicate its 2014 business outlook. A question and answer
session will follow.
In order to participate, please dial the
following numbers (at least 10 minutes before the scheduled start time): United
States and Canada 1-800-510-9691; International 1-617-614-3453; passcode:
15601679.
A live webcast of the call will also be
available on Teva's website at: www.tevapharm.com Please log in at least 10
minutes prior to the conference call in order to download the applicable audio
software.
Following the conclusion of the call, a replay
of the webcast will be available within 24 hours on the Company's website. The
replay can also be accessed until December 17, 2013, at 11:59 p.m. ET by
calling 1-888-286-8010 or 1-617-801-6888; passcode: 73093491#.
TEVA ANNOUNCES ADDITIONAL REGULATORY EXCLUSIVITY FOR TREANDA®
(BENDAMUSTINE HCI) FOR INJECTION
November 27, 2013
Orphan Designation combined with pediatric
extension provides regulatory exclusivity through April 2016 for indolent
B-cell non-Hodgkin lymphoma indication
JERUSALEM--(BUSINESS WIRE)--Nov. 27, 2013--
Teva Pharmaceutical Industries Limited
(NYSE: TEVA) today announced that the U.S. Food and Drug Administration
(FDA) has granted orphan drug exclusivity for TREANDA through October 2015 for
indolent B-cell non-Hodgkin lymphoma (iNHL) that has progressed during or
within six months of treatment with rituximab or a rituximab-containing
regimen. Orphan status is granted to therapies intended to treat diseases or
conditions that affect fewer than 200,000 patients in the United States. With
the previously granted six months of pediatric exclusivity for TREANDA,
regulatory exclusivity for this indication is now extended through April 2016.
“Since 2008, TREANDA has played a significant
role in the treatment of patients with iNHL that has progressed,” said Bill
Campbell, Vice President and General Manager, Teva Oncology. “We are pleased
the FDA has recognized our commitment to treating patients with this rare form
of cancer.”
TREANDA is also indicated for the treatment of
patients with chronic lymphocytic leukemia (CLL). TREANDA has orphan drug exclusivity
for this indication through March 2015. With the previously granted six months
of pediatric exclusivity for TREANDA, regulatory exclusivity for this
indication lasts until September 20, 2015.
Net sales for Treanda in the United States
through the third quarter of 2013 were $531 million.
Indications
TREANDA is indicated for the treatment of
patients with chronic lymphocytic leukemia (CLL). Efficacy relative to
first-line therapies other than chlorambucil has not been established.
TREANDA is indicated for the treatment of
patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed
during or within six months of treatment with rituximab or a
rituximab-containing regimen.
Important Safety Information
Allergic Reactions: Patients with a known
allergic response to bendamustine should not take TREANDA.
Serious Side Effects: TREANDA may cause
serious side effects, including low blood cell counts, infections, unexpected
responses to TREANDA when placed in your blood, sudden and severe allergic
responses, kidney failure due to fast breakdown of cancer cells, other cancers,
and leaking of TREANDA out of your vein and into your surrounding skin. Some of
these side effects, such as low blood counts, infections, and severe allergic
skin responses (when TREANDA was given with allopurinol and other medications
known to cause severe allergic skin responses), have caused death. Tell your
doctor right away if you have any of these side effects.
Changes in Therapy: Some serious side
effects may require changes in therapy, such as lowering the amount of TREANDA
given, stopping the use of TREANDA, or waiting longer than expected between
doses of TREANDA.
Pregnancy: Women should avoid becoming
pregnant while using TREANDA because it may cause fetal harm if you take
TREANDA while pregnant.
Most Common Side Effects: The most common
non-blood-related side effects associated with TREANDA (occurring in ≥15%
of patients) are nausea, fatigue, vomiting, diarrhea, fever, constipation, loss
of appetite, cough, headache, weight loss, difficulty breathing, rash, and
mouth irritation. The most common blood-related side effects associated with
TREANDA (frequency ≥15%) are decreased number of three different types of
white blood cells (infection-fighting cells), low red blood cells
(oxygen-carrying cells), and low platelets (blood-clotting cells).
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No exist to suggest that subject is or was
the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction registered
against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling shareholders,
director, officer or employee of the company is a government official or a
family member or close business associate of a Government official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on Corporate
Governance to identify management and governance. These factors often have been
predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.13 |
|
|
1 |
Rs.101.53 |
|
Euro |
1 |
Rs.85.41 |
INFORMATION DETAILS
|
Report Prepared
by : |
VRN |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
6 |
|
PAID-UP CAPITAL |
1~10 |
6 |
|
OPERATING SCALE |
1~10 |
5 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
6 |
|
--PROFITABILIRY |
1~10 |
6 |
|
--LIQUIDITY |
1~10 |
6 |
|
--LEVERAGE |
1~10 |
6 |
|
--RESERVES |
1~10 |
6 |
|
--CREDIT LINES |
1~10 |
5 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
NO |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
--RBI |
YES/NO |
NO |
|
--EPF |
YES/NO |
NO |
|
|
|
|
|
TOTAL |
|
52 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history (10%) Market trend (10%) Operational size
(10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely
sound financial base with the strongest capability for timely payment of interest
and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate
working capital. No caution needed for credit transaction. It has above
average (strong) capability for payment of interest and principal sums |
Large |
|
56-70 |
A |
Financial & operational
base are regarded healthy. General unfavourable factors will not cause fatal
effect. Satisfactory capability for payment of interest and principal sums |
Fairly
Large |
|
41-55 |
Ba |
Overall operation is considered
normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome
financial difficulties seems comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent.
Repayment of interest and principal sums in default or expected to be in
default upon maturity |
Limited
with full security |
|
<10 |
C |
Absolute credit risk
exists. Caution needed to be exercised |
Credit
not recommended |
|
-- |
NB |
New Business |
-- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.